Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Emerging Therapy and TPP Insights

Thelansis’s “Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Overview

Advanced or metastatic non-squamous non-small cell lung cancer is a biologically heterogeneous thoracic malignancy requiring biomarker-guided systemic treatment. Current management separates tumors with actionable genomic alterations, which may receive targeted therapies, from driver-negative disease managed with immunotherapy, chemotherapy, or combinations according to PD-L1 expression and clinical factors. Despite major advances, acquired resistance, CNS metastases, heterogeneous target expression, and limited durability continue to constrain long-term benefit. The innovation landscape is therefore expanding across multiple precision platforms, including antibody-drug conjugates, next-generation kinase inhibitors, bispecific antibodies, and increasingly CNS-active small molecules. A notable example is the c-MET-directed ADC telisotuzumab vedotin, approved in 2025 for previously treated nonsquamous NSCLC with high c-MET protein overexpression, while HER2-targeted agents such as zongertinib have further broadened biomarker-defined treatment options. For stakeholders, the next frontier in advanced nonsquamous NSCLC is not simply identifying more targets, but delivering durable systemic and intracranial control while anticipating and overcoming molecular mechanisms of resistance.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)